secwatch.observer — SEC 8-K summary
======================================

Issuer:     Prelude Therapeutics Inc (PRLD)
CIK:        0001678660
Form:       8-K
Filed at:   2023-05-19T23:59:59+00:00
Accession:  0001193125-23-149304
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Prelude Therapeutics prices $100M public offering of common stock and pre-funded warrants
--------------------------------------------------------------------------------

- Offering of 3.05M voting shares and 1.45M non-voting shares at $5.75/share; pre-funded warrants for 12.9M shares at $5.7499 each.
- Gross proceeds $100M, net proceeds ~$98.5M; underwriter Morgan Stanley; expected close May 22, 2023.
- Proceeds to advance pipeline (PRT2527, PRT1419, PRT3645, PRT3789) and new SMARCA2 oral molecule R&D.
- Underwriters granted 30-day option to purchase up to 2.6M additional shares of common stock.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1678660/000119312523149304/0001193125-23-149304-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1678660/000119312523149304/d407449d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-149304

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer